Clinical Research Directory
Browse clinical research sites, groups, and studies.
FT839 in Autoimmune Diseases
Sponsor: Fate Therapeutics
Summary
The primary objectives of this trial are to evaluate the safety and tolerability and to determine the maximum tolerated dose (MTD) or recommended Phase 2 dose of FT839 with or without rituximab and/or background therapy and/or conditioning therapy.
Official title: An Open-Label, Multicenter, Phase 1/2 Dose-Escalation and Expansion Trial Evaluating the Safety and Efficacy of FT839 in Participants With Autoimmune Diseases
Key Details
Gender
All
Age Range
18 Years - 70 Years
Study Type
INTERVENTIONAL
Enrollment
446
Start Date
2026-10
Completion Date
2040-10
Last Updated
2026-09-02
Healthy Volunteers
No
Conditions
Interventions
FT839
Single Intravenous (IV) infusion of FT839 administered on Day 1 and Day 4
Locations (1)
Providence Medical Foundation
Fullerton, California, United States